论文部分内容阅读
目的:观察瘤内注射基因工程腺病毒(H101)联合化疗治疗鼻咽癌的近期疗效和不良反应。方法:符合入选标准的鼻咽癌患者54例,给予H101瘤内注射,每天一次,每次一支(5×1011病毒颗粒/0.5ml),连续5天,同时联合PF方案(DDP20mg/m2静滴,d1～5,5-FU500mg/m2静滴,d1～5)或AF方案(ADM50mg/m2静注d1;5-FU500mg/m2静滴,d1～5)化疗,21天为一周期,所有患者均接受2个周期的治疗。结果:在可评价的54例患者中注射病灶的总有效率为77.7%,其中CR10例,PR32例。主要不良反应为注射部位局部疼痛20.4%,非感染性发热40.7%,流感样症状9.3%,未见严重不良事件。结论:在全身化疗的同时瘤内注射基因工程腺病毒(H101)对鼻咽癌有明确的治疗作用,不良反应低,易为患者接受。
Objective: To observe the short-term curative effect and adverse reaction of intra-tumor injection of genetically engineered adenovirus (H101) in combination with chemotherapy for nasopharyngeal carcinoma. Methods: Fifty-four patients with nasopharyngeal carcinoma who met the inclusion criteria were injected intraperitoneally with H101 once a day (5 × 10 11 virus particles / 0.5 ml) for 5 consecutive days. In combination with PF regimen (DDP 20 mg / m 2 Drip, d1 ~ 5,5-FU500mg / m2 intravenous infusion, d1 ~ 5) or AF regimen (ADM50mg / m2 intravenous d1; 5-FU500mg / m2 intravenous infusion, d1 ~ 5) chemotherapy, 21 days for a cycle, Patients received 2 cycles of treatment. Results: The total effective rate of injection in 54 evaluable patients was 77.7%, of which CR10 and PR32. The main adverse reactions were local pain at injection site 20.4%, non-infectious fever 40.7%, flu-like symptoms 9.3%, no serious adverse events. CONCLUSION: Intratumoral injection of genetically engineered adenovirus (H101) with systemic chemotherapy has clear therapeutic effect on nasopharyngeal carcinoma with low adverse reaction and is easy for patients to accept.